- Policy
- Pfizer Korea withdraws a lot of OTC products
- by Lee, Tak-Sun Oct 5, 2020 06:20am
- Pfizer Korea has withdrawn a large number of domestic OTC products. There are only three items left. According to the MFDS on the 28th, Pfizer Korea recently withdrew permission for seven items, including Stresstabs Plus and Caltrate plus. Accordingly, only three items left by Pfizer Korea were Minulet, Alesse, and Cofrel. Even this is no
- Policy
- Bavencio, listed on next month at ₩1,226,243/bottle
- by Kim, Jung-Ju Sep 29, 2020 06:21am
- Bavencio (Avelumab) by Merck, used for the treatment of metastatic Merkel cell carcinoma, will be covered by insurance benefits at &8361;1,226,243 per bottle starting next month. Since it is an expensive drug, it will follow the RSA track, and will be listed as a refund type in which pharmaceutical companies reimburse a certain percent
- Policy
- Kwang Dong competes with Elyson for Nebivolol
- by Lee, Tak-Sun Sep 29, 2020 06:21am
- Kwang Dong is challenging the market by obtaining approval for all three high and low doses of the hypertension treatment 'Nebivolol HCl'. This is the second case that 3 doses have been approved since Elyson was approved. On the 28th, the MFDS approved Kwang Dong's Nebilet M 1.25mg, 2.5mg and 5mg. Nebilet M is a generic for Menarini's Nebile
- Policy
- Immunotherapy Bavencio coverage green lit for skin cancer
- by Lee, Hye-Kyung Sep 28, 2020 06:20am
- The South Korean health authority has granted reimbursement on Merck’s immunotherapy Bavencio injection (avelumab). The Health Insurance Review and Assessment Service (HIRA) plans to accept public opinion on the unveiled revised Notice on Pharmaceuticals for Cancer Patient’s Prescription and Administration until Sept. 17. Without much
- Policy
- Teribone's price will be cut from the 26th
- by Kim, Jung-Ju Sep 28, 2020 06:20am
- The price cut was finally decided in an administrative lawsuit to cut the drug price of Teribone inj 56.5 μg (Teriparatide). Since the company voluntarily withdrew the lawsuit due to lack of profit, no other drug price changes are expected in the future. The Seoul Administrative Court recently ruled against a lawsuit for cancellation of dr
- Policy
- More than 20 companies, to apply for Atozet's generics
- by Lee, Tak-Sun Sep 25, 2020 06:05am
- It is reported that more than 20 pharmaceutical companies have contracted to produce generics for Atozet (Ezetimibe/Atorvastatin) with Chong Kun Dang. Accordingly, it is expected that the number of drugs applied for permission after PMS through bioequivalence test will be lowered by about 15% compared to Chong Kun Dang products. Chong K
- Policy
- The post-assessment system has many problems
- by Lee, Hye-Kyung Sep 25, 2020 06:05am
- The necessity of introducing post-assessment system for prior registration was raised to expand patient access to new drugs, but the government said it needed complex concerns. Choi Gyeong-ho, an official at the insurance pharmaceutical department of the MOHW, said at the 'Non-face-to-face discussion for enhancing patient accessibility of
- Policy
- Better new drug access with pre-listing reimbursement
- by Lee, Hye-Kyung Sep 25, 2020 06:04am
- Pharmaceutical affairs expert argues, to enhance patients’ access to new drugs, the government should induce pharmaceutical companies to voluntarily set and lower generic pricing on their own, while also considering flexible ICER threshold and pre-listing reimbursement. And the expert criticizes the upcoming pilot program, effective from Oc
- Policy
- The generic competition of Circadin PR is intensifying
- by Lee, Tak-Sun Sep 25, 2020 06:04am
- Generics for Circadin PR, a melatonin-based insomnia treatment drug, began to be approved on the 22nd. Kuhnil's Circadin PR was removed from data protection due to the expiration of PMS in June. With the end of PMS, applications for permission for generic drugs were followed, and product approval was finally received this month. Prior to the
- Policy
- The answer is to improve the drug price system
- by Lee, Hye-Kyung Sep 24, 2020 06:20am
- The drug price system should be improved in order to enhance patient access to new drugs such as cancer and rare disease treatments. Through the 'non-face-to-face discussion to enhance patient accessibility of new drugs in the era of COVID-19' hosted by Lee Yong-ho, a member of the National Assembly and hosted by the Future Health Network on
